IGF-1 LR3

IGF-1 LR3 is commonly considered in provider-directed programs focused on the following areas of interest:

• Growth Factor Pathway Support — Often considered in provider-directed programs designed to support insulin-like growth factor (IGF-1) pathway activity.

• Body Composition Support — May be explored within programs focused on body composition and lean-mass-related wellness goals.

• Recovery and Performance — May be considered for patients whose goals include support for recovery and performance-related wellness objectives.

IGF-1 LR3 should be evaluated against applicable prescribing information. Information provided by ALML is intended for healthcare professionals and does not replace independent clinical judgment.

IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 (IGF-1) that includes an arginine substitution and an extended amino acid sequence, resulting in a comparatively longer duration of action relative to native IGF-1. Areas of biological activity include:

Areas being studied include:

• IGF-1 Receptor Interaction — IGF-1 LR3 binds to the insulin-like growth factor 1 (IGF-1) receptor, which is involved in cellular growth and proliferation pathways.

• Extended Duration Profile — The structural modifications in IGF-1 LR3 have been investigated for reducing binding to IGF-binding proteins, supporting a comparatively extended duration of action.

• Cellular Growth and Repair Pathways — IGF-1 receptor activity has been studied for its role in processes associated with cellular growth, maintenance, and repair.

• Metabolic Pathways — IGF-1 pathway activity may influence downstream metabolic processes related to body composition and cellular metabolism.

Clinical use of IGF-1 LR3 varies by patient-specific factors and applicable prescribing information. The treating healthcare professional remains responsible for all clinical decision-making. This information is educational and does not establish clinical efficacy for any specific use.

Healthcare professionals should independently evaluate the available evidence, patient-specific factors, potential risks, and applicable regulatory requirements before considering IGF-1 LR3 for a patient.

Include these considerations:

• Patient-Specific Assessment Required — Providers should consider the patient's medical history, current medications, allergies, pregnancy or breastfeeding status, and other relevant clinical factors before use.

• Use Within Approved and Appropriate Context — IGF-1 LR3 should be evaluated against applicable prescribing information and used only where clinically appropriate for the individual patient.

• Monitor Tolerance and Relevant Clinical Factors — Providers should monitor patient tolerance and relevant clinical factors, including IGF-1-related markers, throughout the course of use.

• Treatment Decisions Remain With the Licensed Healthcare Professional — All treatment, prescribing, and dosing decisions remain solely the responsibility of the appropriately licensed healthcare professional.

ALML provides product and educational information for healthcare professionals. This information is not a substitute for prescribing information, pharmacy labeling, applicable law, or independent clinical judgment.

Verified formulations and strengths will be updated based on current pharmacy availability.